Literature DB >> 30758506

Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease.

Fatima Rodriguez1, David J Maron1, Joshua W Knowles1, Salim S Virani2, Shoutzu Lin3, Paul A Heidenreich1,3.   

Abstract

Importance: Statins decrease mortality in those with atherosclerotic cardiovascular disease (ASCVD), but statin adherence remains suboptimal. Objective: To determine the association between statin adherence and mortality in patients with ASCVD who have stable statin prescriptions. Design, Setting, and Participants: This retrospective cohort analysis included patients who were between ages 21 and 85 years and had 1 or more International Classification of Diseases, Ninth Revision, Clinical Modification codes for ASCVD on 2 or more dates in the previous 2 years without intensity changes to their statin prescription who were treated within the Veterans Affairs Health System between January 1, 2013, and April 2014. Exposures: Statin adherence was defined by the medication possession ratio (MPR). Adherence levels were categorized as an MPR of less than 50%, 50% to 69%, 70% to 89%, and 90% or greater. For dichotomous analyses, adherence was defined as an MPR of 80% or greater. Main Outcomes and Measures: The primary outcome was death of all causes adjusted for demographic and clinical characteristics, as well as adherence to other cardiac medications.
Results: Of 347 104 eligible adults with ASCVD who had stable statin prescriptions, 5472 (1.6%) were women, 284 150 (81.9%) were white, 36 208 (10.4%) were African American, 16 323 (4.7%) were Hispanic, 4093 (1.2%) were Pacific Islander, 1293 (0.4%) were Native American, 1145 (0.3%) were Asian, and 1794 (0.5%) were other races. Patients taking moderate-intensity statin therapy were more adherent than patients taking high-intensity statin therapy (odds ratio [OR], 1.18; 95% CI, 1.16-1.20). Women were less adherent (OR, 0.89; 95% CI, 0.84-0.94), as were minority groups. Younger and older patients were less likely to be adherent compared with adults aged 65 to 74 years. During a mean (SD) of 2.9 (0.8) years of follow-up, there were 85 930 deaths (24.8%). Compared with the most adherent patients (MPR ≥ 90%), patients with an MPR of less than 50% had a hazard ratio (HR; adjusted for clinical characteristics and adherence to other cardiac medications) of 1.30 (95% CI, 1.27-1.34), those with an MPR of 50% to 69% had an HR of 1.21 (95% CI, 1.18-1.24), and those with an MPR of 70% to 89% had an HR of 1.08 (95% CI, 1.06-1.09). Conclusions and Relevance: Using a national sample of Veterans Affairs patients with ASCVD, we found that a low adherence to statin therapy was associated with a greater risk of dying. Women, minorities, younger adults, and older adults were less likely to adhere to statins. Our findings underscore the importance of finding methods to improve adherence.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30758506      PMCID: PMC6439552          DOI: 10.1001/jamacardio.2018.4936

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  34 in total

Review 1.  Meta-analysis of statin effects in women versus men.

Authors:  William J Kostis; Jerry Q Cheng; Jeanne M Dobrzynski; Javier Cabrera; John B Kostis
Journal:  J Am Coll Cardiol       Date:  2012-02-07       Impact factor: 24.094

2.  Statin use in outpatients with obstructive coronary artery disease.

Authors:  Suzanne V Arnold; John A Spertus; Fengming Tang; Harlan M Krumholz; William B Borden; Steven A Farmer; Henry H Ting; Paul S Chan
Journal:  Circulation       Date:  2011-11-07       Impact factor: 29.690

3.  Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education.

Authors:  Melissa Y Wei; Matthew K Ito; Jerome D Cohen; Eliot A Brinton; Terry A Jacobson
Journal:  J Clin Lipidol       Date:  2013-03-13       Impact factor: 4.766

4.  Association between statin adherence and cholesterol level reduction from baseline in a veteran population.

Authors:  Rashid Kazerooni; Jonathan H Watanabe; Mark Bounthavong
Journal:  Pharmacotherapy       Date:  2013-06-06       Impact factor: 4.705

Review 5.  Utilization of and Adherence to Guideline-Recommended Lipid-Lowering Therapy After Acute Coronary Syndrome: Opportunities for Improvement.

Authors:  Benjamin J Hirsh; Nathaniel R Smilowitz; Robert S Rosenson; Valentin Fuster; Laurence S Sperling
Journal:  J Am Coll Cardiol       Date:  2015-07-14       Impact factor: 24.094

6.  Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines.

Authors:  Fatima Rodriguez; Shoutzu Lin; David J Maron; Joshua W Knowles; Salim S Virani; Paul A Heidenreich
Journal:  Am Heart J       Date:  2016-09-29       Impact factor: 4.749

7.  Medication adherence and readmission after myocardial infarction in the Medicare population.

Authors:  Yuting Zhang; Cameron M Kaplan; Seo Hyon Baik; Chung-Chou H Chang; Judith R Lave
Journal:  Am J Manag Care       Date:  2014       Impact factor: 2.229

8.  Gender Disparities in Lipid-Lowering Therapy in Cardiovascular Disease: Insights from a Managed Care Population.

Authors:  Fatima Rodriguez; Temitope O Olufade; Dena R Ramey; Howard S Friedman; Prakash Navaratnam; Kim Heithoff; JoAnne M Foody
Journal:  J Womens Health (Larchmt)       Date:  2016-02-18       Impact factor: 2.681

9.  Treatment adherence and risk of death after a myocardial infarction.

Authors:  R I Horwitz; C M Viscoli; L Berkman; R M Donaldson; S M Horwitz; C J Murray; D F Ransohoff; J Sindelar
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

10.  Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry.

Authors:  Michael G Nanna; Ann Marie Navar; Pearl Zakroysky; Qun Xiang; Anne C Goldberg; Jennifer Robinson; Veronique L Roger; Salim S Virani; Peter W F Wilson; Joseph Elassal; L Veronica Lee; Tracy Y Wang; Eric D Peterson
Journal:  JAMA Cardiol       Date:  2018-08-01       Impact factor: 14.676

View more
  59 in total

1.  Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.

Authors:  Kausik K Ray; Robert M Stoekenbroek; David Kallend; Toshiyuki Nishikido; Lawrence A Leiter; Ulf Landmesser; R Scott Wright; Peter L J Wijngaard; John J P Kastelein
Journal:  JAMA Cardiol       Date:  2019-11-01       Impact factor: 14.676

2.  A controlled trial of dissemination and implementation of a cardiovascular risk reduction strategy in small primary care practices.

Authors:  Samuel Cykert; Thomas C Keyserling; Michael Pignone; Darren DeWalt; Bryan J Weiner; Justin G Trogdon; Thomas Wroth; Jacqueline Halladay; Monique Mackey; Jason Fine; Jung In Kim; Crystal Cene
Journal:  Health Serv Res       Date:  2020-10-13       Impact factor: 3.402

3.  Adherence to antihypertensive medication and its predictors among non-elderly adults in Japan.

Authors:  Shiori Nishimura; Hiraku Kumamaru; Satoshi Shoji; Mitsuaki Sawano; Shun Kohsaka; Hiroaki Miyata
Journal:  Hypertens Res       Date:  2020-04-20       Impact factor: 3.872

Review 4.  Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?

Authors:  Arman Qamar; Peter Libby
Journal:  Curr Cardiol Rep       Date:  2019-06-27       Impact factor: 2.931

5.  PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021.

Authors:  Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska
Journal:  Arch Med Sci       Date:  2021-11-08       Impact factor: 3.318

Review 6.  Health Disparities Across the Continuum of ASCVD Risk.

Authors:  Ankita Devareddy; Ashish Sarraju; Fatima Rodriguez
Journal:  Curr Cardiol Rep       Date:  2022-07-05       Impact factor: 3.955

Review 7.  Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?

Authors:  Matthew R Deshotels; Salim S Virani; Christie M Ballantyne
Journal:  Curr Cardiol Rep       Date:  2021-07-16       Impact factor: 2.931

8.  Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia.

Authors:  Chia-Pin Lin; Ying-Chang Tung; Fu-Chih Hsiao; Chia-Hung Yang; Yi-Wei Kao; Yu-Sheng Lin; You-Chia Chu; Pao-Hsien Chu
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-29       Impact factor: 3.738

9.  Clinical Pharmacist Outreach to Increase Statin Use for Patients with Cardiovascular Disease in a Safety-Net Healthcare System.

Authors:  Paul Cornelison; Joel C Marrs; Sarah L Anderson
Journal:  Am Health Drug Benefits       Date:  2021-06

10.  Genome-Wide Variants Associated With Longitudinal Survival Outcomes Among Individuals With Coronary Artery Disease.

Authors:  Jennifer R Dungan; Xue Qin; Melissa Hurdle; Carol S Haynes; Elizabeth R Hauser; William E Kraus
Journal:  Front Genet       Date:  2021-06-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.